XML 46 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2

Fair Value Measurements (Acquisition of CyDex) (Details) - Cydex Pharmaceuticals, Inc - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Credit Derivatives [Line Items]
Amount Of Revenue For Contingent Consideration	$ 15.0
Contingent Consideration Classified as Equity
Credit Derivatives [Line Items]
Annual revenue subject to revenue sharing	$ 28.0	$ 22.5
Revenue volatility	25.00%	25.00%
Average probability	92.00%	73.00%
Sales beta	0.30	0.40
Credit rating	BB	BB
Equity risk premium	6.00%	6.00%

X

- Definition

Amount of revenue for contingent consideration.

+ References

No definition available.

+ Details

Name:	lgnd_AmountOfRevenueForContingentConsideration
Namespace Prefix:	lgnd_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Fair Value Inputs, Annual Revenue Subject To Revenue Sharing

+ References

No definition available.

+ Details

Name:	lgnd_FairValueInputsAnnualRevenueSubjectToRevenueSharing
Namespace Prefix:	lgnd_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Average Probability of Commercialization

+ References

No definition available.

+ Details

Name:	lgnd_FairValueInputsAverageOfProbabilityOfCommercialization
Namespace Prefix:	lgnd_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Fair Value Inputs, Credit Rating

+ References

No definition available.

+ Details

Name:	lgnd_FairValueInputsCreditRating
Namespace Prefix:	lgnd_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Fair Value Inputs, Sales Beta

+ References

No definition available.

+ Details

Name:	lgnd_FairValueInputsSalesBeta
Namespace Prefix:	lgnd_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CreditDerivativesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueAssumptionsExpectedVolatilityRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Percentage above fair value that an investor seeking to acquire control of an entity will pay, used as an input to measure fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueInputsControlPremium
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FairValueByLiabilityClassAxis=us-gaap_ContingentConsiderationClassifiedAsEquityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: